Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein Pf START1

With resistance to most antimalarials increasing, it is imperative that new drugs are developed. We previously identified an aryl acetamide compound, MMV006833 (M-833), that inhibited the ring-stage development of newly invaded merozoites. Here, we select parasites resistant to M-833 and identify mutations in the START lipid transfer protein (PF3D7_0104200, PfSTART1). Introducing Pf START1 mutations into wildtype parasites reproduces resistance to M-833 as well as to more potent analogues. Pf START1 binding to the analogues is validated using organic solvent-based Proteome Integral Solubility Alteration (Solvent PISA) assays. Imaging of invading merozoites shows the inhibitors prevent the development of ring-stage parasites potentially by inhibiting the expansion of the encasing parasitophorous vacuole membrane. The Pf START1-targeting compounds also block transmission to mosquitoes and with multiple stages of the parasite’s lifecycle being affected, Pf START1 represents a drug target with a new mechanism of action.